Efficacy and safety of first line Vincristine with doxorubicin, bleomycin and dacarbazine (ABOD) for Hodgkin's lymphoma: A single Institute experience


Creative Commons License

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., ...More

Asian Pacific Journal of Cancer Prevention, vol.15, no.20, pp.8715-8718, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 20
  • Publication Date: 2014
  • Doi Number: 10.7314/apjcp.2014.15.20.8715
  • Journal Name: Asian Pacific Journal of Cancer Prevention
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.8715-8718
  • Keywords: Hodgkin's lymphoma, chemotherapy, vincristine, prognostic factors, CHEMOTHERAPY, ABVD, DISEASE, TRIAL, THERAPY, BEACOPP, MOPP
  • Lokman Hekim University Affiliated: Yes

Abstract

Background: ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen in Hodgkin's lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacy and safety of O as a part of ABOD in HL. Materials and Methods: Patients who had ABOD were enrolled. Stage I-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute Common Toxicity Criteria was used for toxicity. Results: Seventy-nine HL patients in our center between 2003 and 2007 were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their third decade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% for early relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4% for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients had autologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longer in early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02; respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT (p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicityrelated deaths. Conclusions: ABOD seems to be effective with managable toxicity in HL, even in those with poor prognostic factors.